The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 3, 2010, Pages 596-604

  Rychli, K ^a   Kaun, C ^a   Hohensinner, P J ^a   Rega, G ^a   Pfaffenberger, S ^a   Vyskocil, E ^a   Breuss, J M ^a   Furnkranz, A ^b   Uhrin, P ^a   Zaujec, J ^a   Niessner, A ^a   Maurer, G ^a   Huber, K ^b   Wojta, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Angiogenesis; Angiopoietin; Cytokine; Oncostatin M

Indexed keywords

ANGIOPOIETIN 2; GLYCOPROTEIN 130 RECEPTOR; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; RECEPTOR PROTEIN; STAT PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UMBILICAL VEIN;

ANGIOPOIETIN-2; ANIMALS; CELLS, CULTURED; CORONARY VESSELS; CYTOKINE RECEPTOR GP130; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; JANUS KINASES; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA SUBUNIT; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TIME FACTORS; TISSUE CULTURE TECHNIQUES; UMBILICAL VEINS; UP-REGULATION;

EID: 77949303683     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03741.x     Document Type: Article

References (39)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-60.
2. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003, 1:1356-70.
3. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007, 10:149-66.
4. Vasse M, Pourtau J, Trochon V, Muraine M, Vannier JP, Lu H, Soria J, Soria C. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999, 19:1835-42.
5. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271:736-41.
6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
7. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004, 11:517-27.
8. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-27.
9. Weiss TW, Speidl WS, Kaun C, Rega G, Springer C, Macfelda K, Losert UM, Grant SL, Marro ML, Rhodes AD, Fuernkranz A, Bialy J, Ullrich R, Holzmann P, Pacher R, Maurer G, Huber K, Wojta J. Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res 2003, 59:628-38.
10. Repovic P, Fears CY, Gladson CL, Benveniste EN. Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 2003, 22:8117-24.
11. Faffe DS, Flynt L, Mellema M, Whitehead TR, Bourgeois K, Panettieri RA, Silverman ES, Shore SA. Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1040-8.
12. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-6.
13. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-8.
14. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-9.
15. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
16. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006, 98:1014-23.
17. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006, 312:630-41.
18. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-6.
19. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002, 99:11205-10.
20. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-8.
21. Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J. Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 2007, 73:77-83.
22. Wojta J, Zoellner H, Gallicchio M, Hamilton JA, McGrath K. Gamma-interferon counteracts interleukin-1 alpha stimulated expression of urokinase-type plasminogen activator in human endothelial cells in vitro. Biochem Biophys Res Commun 1992, 188:463-9.
23. al-Azhary DB, Wojta J, Binder BR. Fibrinolytic system of cultured rabbit aortic endothelial cells. Thromb Res 1994, 75:559-68.
24. Wojta J, Zoellner H, Gallicchio M, Filonzi EL, Hamilton JA, McGrath K. Interferon-alpha 2 counteracts interleukin-1 alpha-stimulated expression of urokinase-type plasminogen activator in human foreskin microvascular endothelial cells in vitro. Lymphokine Cytokine Res 1994, 13:133-8.
25. Demyanets S, Kaun C, Rychli K, Rega G, Pfaffenberger S, Afonyushkin T, Bochkov VN, Maurer G, Huber K, Wojta J. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. Am J Physiol Heart Circ Physiol 2007, 293:H1962-8.
26. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007, 100:174-90.
27. Gomez-Lechon MJ. Oncostatin M: signal transduction and biological activity. Life Sci 1999, 65:2019-30.
28. Eiken HG, Oie E, Damas JK, Yndestad A, Bjerkeli V, Aass H, Simonsen S, Geiran OR, Tonnessen T, Christensen G, Froland SS, Gullestad L, Attramadal H, Aukrust P. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 2001, 31:389-97.
29. Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, McIntyre TM. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997, 100:158-68.
30. Chen X, Liu W, Wang J, Wang X, Yu Z. STAT1 and STAT3 mediate thrombin-induced expression of TIMP-1 in human glomerular mesangial cells. Kidney Int 2002, 61:1377-82.
31. Lin SK, Kok SH, Yeh FT, Kuo MY, Lin CC, Wang CC, Goldring SR, Hong CY. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Arthritis Rheum 2004, 50:785-93.
32. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 2006, 54:3152-62.
33. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996, 93:407-11.
34. Sandhu R, Teichert-Kuliszewska K, Nag S, Proteau G, Robb MJ, Campbell AI, Kuliszewski MA, Kutryk MJ, Stewart DJ. Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. Cardiovasc Res 2004, 64:115-24.
35. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004, 43:423-8.
36. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004, 110:2355-60.
37. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-80.
38. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem 2001, 276:47038-45.
39. Mahboubi K, Kirkiles-Smith NC, Karras J, Pober JS. Desensitization of signaling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signaling 3. J Biol Chem 2003, 278:25014-23.